Toggle menu
  • sales@assaygenie.com
  • Select Currency: USD
    • Euro
    • US Dollar
  • 25 Windsor Place Dublin 2 D02 VY42 Ireland
  • +353 15639720
  • Sign in Register
  • Compare
  • Cart
Assay Genie

Filter by Tag

  • Apoptosis
  • Cancer
  • Cell Signalling
  • Cellular Processes
  • COVID-19
  • Disease
  • Immunology
  • Interleukins
  • Microbiology
  • Neuroscience
  • PhD and Post Doc
  • Protocols
  • T cells
  • Therapeutics
  • Whitepaper
  • Home
  • Blog
  • Biosimilar

Blog

Tesnatilimab: Unveiling the Potential of Anti-CD47 in Cancer Research

Tesnatilimab: Unveiling the Potential of Anti-CD47 in Cancer Research

Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune responses.What is the mechanism of action for Tesnatilimab?Tesnatilimab binds to the CD47 receptor on cancer cells, enhancing their phagocytosis by macrophages and other immune cells.What are the clinical applications of Tesnatilimab?It is being explored for its efficacy in treating various cancers, including hematologic malignancies and solid tumors.Is Tesnatilimab safe?Studies highlight its potential with a manageable safety profile, though some patients may experience mild-to-moderate immune-relat …
read more
10th Dec 2024 Miren Ruiz de Eguilaz
Etigilimab: Unveiling the Role of Anti-TIGIT in Cancer Research

Etigilimab: Unveiling the Role of Anti-TIGIT in Cancer Research

Key Facts About EtigilimabWhat is Etigilimab?Etigilimab is an anti-TIGIT monoclonal antibody being studied for its potential role in cancer immunotherapy.What role does Etigilimab play in targeting TIGIT?Etigilimab inhibits TIGIT, a receptor that suppresses T-cell activity, enhancing the immune system's ability to combat tumors.What are the clinical applications of Etigilimab?Etigilimab is being explored in combination therapies for treating various cancers, leveraging its immune-boosting capabilities.1.) Understanding EtigilimabEtigilimab, also known by its research name MGA271, is a monoclonal antibody that targets TIGIT (T-cell immunoreceptor with Ig and ITIM domains). TIGIT …
read more
10th Dec 2024 David Lee
Varlilumab: Unlocking CD27’s Potential in Cancer Research

Varlilumab: Unlocking CD27’s Potential in Cancer Research

What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is the mechanism of action for Varlilumab?Varlilumab enhances immune responses by activating CD27 signaling, promoting T-cell proliferation, and regulating immune suppression in cancer.What are the clinical applications of Varlilumab?Varlilumab has been studied in combination therapies, particularly with immune checkpoint inhibitors like nivolumab, for cancers such as melanoma and glioblastoma.1.) Understanding VarlilumabVarlilumab (CDX-1127) is a human monoclonal antibody developed by Celldex The …
read more
5th Dec 2024 Chris McNally
Vorsetuzumab: Advancing Cancer Research with CD70 Targeting

Vorsetuzumab: Advancing Cancer Research with CD70 Targeting

What You Need to Know About VorsetuzumabWhat is Vorsetuzumab?Vorsetuzumab is a monoclonal antibody targeting CD70, a protein found in various cancers. It shows promise for advancing cancer immunotherapy due to its tumor-specific activity.What is Vorsetuzumab mafodotin?Vorsetuzumab mafodotin is an antibody-drug conjugate combining vorsetuzumab with a cytotoxic agent. This combination delivers targeted therapy, killing CD70-positive cancer cells.Why is Vorsetuzumab significant?Its high specificity for cancer cells and potential to enhance immune response make it a key focus in emerging oncology research.1.) Understanding VorsetuzumabVorsetuzumab is a targeted therapeutic age …
read more
27th Nov 2024 David Lee
Talacotuzumab: Exploring CD123-Targeting Therapies in AML and MDS Research

Talacotuzumab: Exploring CD123-Targeting Therapies in AML and MDS Research

Key Facts About TalacotuzumabWhat is Talacotuzumab?Talacotuzumab is a monoclonal antibody designed to target CD123, a protein commonly found on the surface of certain blood cancer cells.How does Talacotuzumab work?It binds to CD123, recruiting the body’s immune cells to destroy cancer cells, making it a targeted and innovative approach in cancer therapy.What are Talacotuzumab’s potential uses?Talacotuzumab has been studied for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), offering hope for patients with these challenging conditions.1.) Understanding TalacotuzumabTalacotuzumab is a humanized monoclonal antibody developed to target CD123, a key marker …
read more
27th Nov 2024 David Lee
Magrolimab: Unveiling the Role of Anti-CD47 in Cancer Research and Beyond

Magrolimab: Unveiling the Role of Anti-CD47 in Cancer Research and Beyond

What You Need to Know About MagrolimabWhat is Magrolimab?Magrolimab is an anti-CD47 monoclonal antibody that targets the "don't eat me" signal on cancer cells, promoting their destruction by the immune system.Is Magrolimab safe?Magrolimab has shown a manageable safety profile in clinical trials, though side effects such as anemia and infusion reactions have been reported.What is the mechanism of action for Magrolimab?Magrolimab works by blocking CD47, a protein that helps cancer cells evade immune attack, thereby enabling macrophages to target and eliminate these cells.1.) Understanding MagrolimabMagrolimab is a groundbreaking therapeutic antibody developed to target CD47, a pr …
read more
27th Nov 2024 David Lee
Elotuzumab: Revolutionizing Multiple Myeloma Treatment and Research Applications

Elotuzumab: Revolutionizing Multiple Myeloma Treatment and Research Applications

Quick Facts About ElotuzumabWhat is Elotuzumab?Elotuzumab is a monoclonal antibody designed to enhance the immune system's ability to detect and destroy multiple myeloma cells. It targets the SLAMF7 protein, which is present on both myeloma and immune natural killer (NK) cells.How does Elotuzumab work?Elotuzumab activates NK cells by binding to SLAMF7, boosting their ability to attack cancer cells. It also directly marks myeloma cells for immune system destruction, making it a dual-action therapy.What is Elotuzumab used for?Primarily, Elotuzumab is used in combination therapies for relapsed or refractory multiple myeloma. These include pairings with drugs like lenalidomide, pom …
read more
26th Nov 2024 David Lee
Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars

Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars

Key Facts: PembrolizumabIs Pembrolizumab Safe?Pembrolizumab is widely recognized as safe for most patients, with side effects ranging from mild to severe. Commonly reported side effects include fatigue, rash, and immune-related complications such as colitis or pneumonitis.What is the Mechanism of Action for Pembrolizumab?Pembrolizumab functions by inhibiting the PD-1 pathway, a mechanism that tumors often exploit to evade immune detection. By blocking this pathway, Pembrolizumab enhances the immune system’s ability to identify and destroy cancer cells.Does Pembrolizumab Lower IgG4 Levels?Research has shown that Pembrolizumab can reduce IgG4 levels, which may influence immune mo …
read more
26th Nov 2024 David Lee
Daratumumab: Advancing Research in Multiple Myeloma and Beyond

Daratumumab: Advancing Research in Multiple Myeloma and Beyond

Key Facts About DaratumumabWhat is Daratumumab?Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells.How does Daratumumab work?It binds to CD38, triggering immune-mediated destruction of cancer cells through mechanisms like complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.What are the clinical applications of Daratumumab?Daratumumab is primarily used in the treatment of multiple myeloma, both as a monotherapy and in combination with other therapies. Research is also exploring its potential in other hematologic cancers.1.) Understanding DaratumumabDaratumumab is a groundbreaking t …
read more
26th Nov 2024 David Lee
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
Assay Genie
  • 25 Windsor Place
    Dublin 2
    D02 VY42
    Ireland
  • Call us at +353 15639720

Navigate

  • Services
  • Resources
  • Contact Us
  • Sitemap

International Websites

assaygenie.kr

assaygenie.jp

assaygenie.de

Categories

  • ELISA Kits
  • Multiplex ELISA
  • Cellular Assays
  • Antibodies
  • In Vivo Antibodies
  • Proteins

© Assay Genie.